[ad_1] Also available in Italy atezolizumab, first anti-PD-L1 immunotherapy approved by AIFA for the treatment of monotherapy of adult patients with non-small cell lung cancer locally advanced or metastatic, previously subjected to …
Read More »[ad_1] Also available in Italy atezolizumab, first anti-PD-L1 immunotherapy approved by AIFA for the treatment of monotherapy of adult patients with non-small cell lung cancer locally advanced or metastatic, previously subjected to …
Read More »